Biotheranostics, Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Jun 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 22, 2027.
Recent changes
- 1 term has ended since Aug 24, 2026
- Aug 30 US 11,430,544 Identification of Tumors and Tissues · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,856,533 | Predicting breast cancer treatment outcome In force · High confidence | In force | High confidence | |
| US 11,078,538 | Post-Treatment Breast Cancer Prognosis In force · Medium confidence | In force | Medium confidence | |
| US 12,460,265 | Post-Treatment Breast Cancer Prognosis In force · Medium confidence | In force | Medium confidence | |
| US 11,549,148 | Neuroendocrine Tumors In force · Medium confidence | In force | Medium confidence | |
| US 12,595,516 | Neuroendocrine Tumors In force · Medium confidence | In force | Medium confidence | |
| US 12,215,390 | Integration of Tumor Characteristics with Breast Cancer Index In force · Medium confidence | In force | Medium confidence | |
| US 10,253,369 | Predicting Likelihood of Response to Combination Therapy In force · High confidence | In force | High confidence | |
| US 11,530,448 | Integration of Tumor Characteristics with Breast Cancer Index In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 3 patents in force now held by others · 1 lapsed for an unpaid fee · 11 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 11 abandoned · 3 no status recorded
Showing 1 to 10 of 17, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/002,028 | Integration of Tumor Characteristics with Breast Cancer Index | Dec 26, 2024 | Pending |
| 17/854,909 | Identification of Tumors and Tissues | Jun 30, 2022 | Pending |
| 17/513,640 | Predicting Breast Cancer Recurrence | Oct 28, 2021 | Pending |
| 17/502,355 | Oct 15, 2021 | No status recorded | |
| 16/701,000 | Dec 2, 2019 | No status recorded | |
| 16/404,424 | Grading of Breast Cancer | May 6, 2019 | Abandoned |
| 15/807,474 | Predicting Breast Cancer Treatment Outcome | Nov 8, 2017 | Abandoned |
| 15/582,125 | Determining Tumor Origin | Apr 28, 2017 | Abandoned |
| 15/470,818 | Prostate Cancer Survival and Recurrence | Mar 27, 2017 | Abandoned |
| 14/483,108 | Predicting Breast Cancer Recurrence | Sep 10, 2014 | Abandoned |
10 of 17 applications shown.
Pro members see all 17 published applications.